pharma · COVID-19 · Cystic Fibrosis · ARCT
Arcturus Therapeutics
Arcturus Therapeutics Holdings
Arcturus Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker ARCT. Primary therapeutic focus areas include COVID-19, Cystic Fibrosis, Influenza, Human, SARS-CoV-2, Covid1
10285 Science Center Dr, San Diego, California 92121, US HQ
2013 Founded
157 Employees
Public company Type
ARCT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10285 Science Center Dr, San Diego, California 92121, US
- Founded
- 2013
- Employees
- 157
- Programs
- 13
- Drugs
- 7
- Patents
- 55
SARS-CoV-2 mRNA Vaccine ARCT-021
Phase 2 · mab · Hematopoietic and Lymphatic System Neoplasm
SARS-CoV-2 mRNA Vaccine ARCT-021 for Hematopoietic and Lymphatic System Neoplasm is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Internal code RG1125827
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Arcturus Therapeutics Holdings
- Phase
- Phase 2
- Modality
- mab
- Indication
- Hematopoietic and Lymphatic System Neoplasm
- Status
- active
- Trials
- 1